
usd jul pm et
summari compani provid advanc scientif instrument relat product servic
world-wide pharmaceut industri govern academ custom
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr pm stock trade
risk assess reflect benefit strong
track record technolog innov divers
global client base see benefit partial off-set
somewhat volatil sale pattern howev note
sale growth neg quarter
 also see risk associ
strength sever much larger diversifi
competitor must go particularli
seek market share gain market
competitor may alreadi firmli entrench
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
inc drop target price
ep estim -- roughli
line histor forward price-to-earnings averag
maintain ep
estim ep vs met
consensu revenu grew yoy led
diagnost segment oper
profit continu perform well
top line revenu growth yoy
discoveri analyt grew sale
yoy howev demand analyt
instrument china significantli weaken
quarter think -china trade war
neg impact cost
competit busi
worsen yoy addit cash
oper first half fell yoy
receiv inventori grow
mid-teen versu low-singl digit
revenu think balanc sheet trend
put risk miss futur revenu
growth oper margin target /colin
oct ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc provid technolog product servic
diagnost research environment industri laboratori servic market compani oper
two segment discoveri analyt solut revenu oper profit
diagnost revenu oper profit
discoveri analyt solut da technolog product segment help life
scienc research better understand diseas develop treatment addit allow
monitor manag contamin toxic chemic impact environ food
suppli da serv life scienc appli market describ
life scienc market serv da consist research market laboratori servic market
life scienc product sold da support pharmaceut biotech compani academ
institut discov develop better treatment therapeut fight diseas da
onesourc laboratori servic busi also provid life scienc custom servic design improv
laboratori product time reduc mainten cost
appli market serv da consist environment food industri market environment
custom use da analyt technolog servic understand character
environ like air water soil qualiti exampl da solut help ensur complianc
regulatori standard protect puriti world water suppli detect harm substanc
includ trace metal lead organ pollut pesticid food produc use da
instrument confirm food qualiti includ level moistur grain level fat butter
well detect presenc potenti danger contamin lead mercuri milk
industri custom chemic semiconductor electron energi lubric petrochem
produc use da technolog primarili qualiti assur capac
diagnost segment sell product servic hospit medic lab clinician medic
research profession focu reproduct health autoimmun diseas screen appli
genom diagnost product use clinic set provid earli detect genet
disord pregnanc earli childhood also use infecti diseas test
segment also serv laboratori custom util instrument reagent softwar
test screen genet abnorm certain disord diseas includ syndrom
hypothyroid infertil variou metabol condit diagnost product also support
genom research analysi lab workflow use next-gener dna sequenc applic
oncolog drug discoveri
employ approxim sale servic repres countri directli market
servic product across globe market lack sale servic forc util
third-parti distributor get product custom
product sold often serv custom conduct cutting-edg research develop
 biopharmaceut medic industri applic accordingli must consist invest
 provid product anticip continu evolv need technolog
advanc custom base spent million revenu program
corpor strategi histor pursu capit alloc strategi balanc small
bolt-on acquisit share repurchas dividend debt reduct deviat
strategi howev make major acquisit expand diagnost busi acquir immun
decemb billion increas invest capit compar
immun lead diagnost compani focus autoimmun infecti diseas allergi test
financi trend sale grown billion billion repres
three-year compound annual growth rate compound-annual-growth-rate sale growth materi impact
immun acquisit drove sale increas adjust pre-tax incom per
share grew three-year compound-annual-growth-rate period aid expans adjust
pre-tax incom margin signific financi
leverag risk view ebita-to-interest coverag roughli
senior vice-president
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
lst sub-industri
next year expect earn growth
remain posit slow rate achiev
posit earn growth
view strong growth public
fund medic research demand growth
emerg market expect factor
balanc slower pace
biopharmaceut spend growth
higher oper cost due tariff
budget nation institut
nih grow rapidli
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih
fy sep budget grew vs prior
year follow growth
fy fy respect growth
mark major acceler averag
fy fy believ
boost sale lst
sub-industri grew
expect lst firm
continu see strong demand
publicly-fund lab
prolifer advanc health care around
world also continu drive demand
growth lst firm trend
remain particularli strong china
emerg market rapidli grow middl
class gain access advanc health
care drive suppli need new expand
medic research lab facil
estim trend drove growth
lst sub-industri sale
asia-pacif region expect
continu posit long-term driver
contrast strong demand growth
expect publicly-fund client think
biopharmaceut firm moder
 spend growth year ahead
estim total
spend
biopharmaceut compani grew
annual averag expect slow
howev mani
biopharmaceut firm look limit spend
growth off-set recent revenu headwind
patent expir public scrutini
high drug price larg swath biopharma
 typic flow lst firm suppli
 depart research tool
softwar well contract servic
accordingli think slowdown
biopharma growth reduc tailwind
mani lst firm receiv
client group recent year
also expect recent escal trade
tariff neg impact lst earn
growth analyt
instrument maker lst sub-industri
global suppli chain see
strong oper profit growth
first half brought lower profit
mani busi think shift
relat tariff impos -china
trade septemb rais
product cost instrument maker
escal may
end sight current trade
disput expect tariff continu
pressur sale growth oper margin
sub-industri
year-to-d juli
servic rose broader
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
keep target ep estim
roughli line peer averag ep vs
consensu lower ep estim keep
show strong total revenu growth yoy aid
acquisit immun post encourag organ
revenu growth sinc close exclud acquisit total organ
revenu growth strong yoy experienc broad-bas growth
particularli robust demand drug discoveri equip biopharma firm
well immunodiagnost appli genom end market howev
adjust pre-tax incom keep pace revenu growth yoy
due higher sg margin interest debt think
improv margin work year immun integr
still feel stock alreadi near full valu /colin scarola
rais target slightli peer
forward ep estim near high end
five-year rang ep vs ahead
view rais ep estim ep
estim sale aid acquisit rose
organ growth healthi segment discoveri analyt
solut rose organ growth diagnost rose
organ growth discoveri analyt sale driven strong consum
uptak new imag analyt instrument within diagnost
sale driven signific growth emerg market aid
acquisit tulip euroimmun grew mid-teen
encourag signific oper margin expans basi point
aid supplier consolid follow basi point
declin /jeffrey loo cfa
analyst research note compani news
pm et cfra maintain sell opinion share inc
drop target price ep
estim -- roughli line histor forward price-to-earnings averag
maintain ep estim ep vs met
consensu revenu grew yoy led diagnost segment
oper profit continu perform well top line revenu
growth yoy discoveri analyt grew sale yoy
howev demand analyt instrument china significantli weaken
quarter think -china trade war neg impact
cost competit busi segment saw adjust
oper margin worsen yoy addit cash oper
first half fell yoy receiv inventori grow
mid-teen versu low-singl digit revenu think balanc sheet
trend put risk miss futur revenu growth oper margin
pm et cfra maintain sell opinion share inc
keep target ep
estim roughli line histor forward price-to-earnings averag also
maintain ep estim ep vs beat
consensu report revenu grew yoy exclud exchang
rate effect organ growth higher mark slowdown
organ growth discoveri analyt solut da
revenu saw sale fall yoy neg impact
govern shutdown januari partial off-set growth
biopharma sale diagnost sale grew sale yoy driven
strong demand autoimmun genom test also improv oper
leverag quarter basi point yoy improv gross margin
impress steadi improv oper expens
continu think valuat overli expens given slow organ
growth particularli da segment /colin scarola
pm et cfra lower opinion share inc sell
hold keep target ep
estim roughli line long-term forward price-to-earnings averag also
maintain ep estim lower opinion share
primarili valuat reason note share current trade
consensu forward ep estim
five- ten-year forward price-to-earnings averag respect might find
current premium valuat justifi expect ep growth materi
acceler think like growth
moder follow banner year growth adjust pre-tax incom per
share also note show slowdown discoveri
analyt revenu yoy sale growth first nine
month think diagnost sale growth like
slow organ growth line peer averag
mid-singl digit /colin scarola
et cfra keep hold opinion share inc
keep target ep estim --
roughli line long-term forward price-to-earnings averag ep vs
consensu lower ep estim
start revenu growth yoy driven
acquisit immun organ revenu growth
yoy diagnost segment revenu continu experi
robust demand increas sale yoy organ especi strong
perform genom test busi grew discoveri
analyt segment revenu experienc slowdown howev
growth first nine month think
driven increas competit custom life scienc
expect improv margin work year
immun integr ep growth like slow materi without
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
